معرفی
Kim Lewis is a University Distinguished Professor of Biology and Director of the Antimicrobial Discovery Center at Northeastern University. His research focuses on persister cells, microbiomes, and uncultured bacteria, with groundbreaking contributions to antibiotic discovery. Key achievements include identifying mechanisms of persister formation and discovering teixobactin (2015), the first antibiotic with no detectable resistance, and darobactin (2019) from the microbiome. His work addresses antibiotic resistance, Lyme disease treatment, and biowarfare threats. Lewis has received multiple recognitions, including being named a Highly Cited Researcher (2018–2021) and a Fellow of the American Association for the Advancement of Science (2018).
His lab develops novel drug discovery platforms, such as microfluidics-based screening for antibiotics. The Antimicrobial Discovery Center, funded by NIH and private foundations, translates research into clinical applications. Lewis collaborates with institutions like NovoBiotic Pharmaceuticals and has spun off companies contributing to economic growth. His research also explores gut microbiota's role in health, including mental disorders and chronic diseases.
